{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:38:40Z","timestamp":1773423520144,"version":"3.50.1"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Influenza virus infections are known to persist longer in patients with underlying diseases, including respiratory tract diseases, and tend to become complicated by secondary influenza-associated infections, such as pneumonia. To assess the efficacy and safety of the novel anti-influenza virus drug peramivir in high-risk patients, we conducted a clinical trial of patients with diabetes or chronic respiratory tract diseases and patients being treated with drugs that suppress immune function. In this multicenter, uncontrolled, randomized, double-blind study, peramivir was intravenously administered at 300 or 600 mg\/day for 1 to 5 days, as needed. Efficacy was investigated in 37 patients (300 mg,<jats:italic>n<\/jats:italic>= 18 patients; 600 mg,<jats:italic>n<\/jats:italic>= 19 patients). The median durations of influenza illness were 68.6 h (90% confidence interval, 41.5 to 113.4 h) overall, 114.4 h (90% confidence interval, 40.2 to 235.3 h) in the 300-mg group, and 42.3 h (90% confidence interval, 30.0 to 82.7 h) in the 600-mg group. The hazard ratio for the 600-mg group compared to the 300-mg group was 0.497 (90% confidence interval, 0.251 to 0.984), and the duration of influenza illness was significantly shorter in the 600-mg group than in the 300-mg group. Among the 42 patients in the safety analysis set, adverse events occurred in 73.8% and adverse drug reactions in 33.3%. No adverse events were particularly problematic clinically, and all patients recovered quickly from all events. The measured blood drug concentrations showed no tendency toward accumulation. Drug accumulation with repeated doses was thus considered to be of little concern. Intravenous peramivir appears to offer a potentially useful treatment for high-risk patients in the future.<\/jats:p>","DOI":"10.1128\/aac.01718-10","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T03:18:51Z","timestamp":1301973531000},"page":"2803-2812","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":94,"title":["Intravenous Peramivir for Treatment of Influenza A and B Virus Infection in High-Risk Patients"],"prefix":"10.1128","volume":"55","author":[{"given":"Shigeru","family":"Kohno","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kida","sequence":"additional","affiliation":[{"name":"Department of Disease Control, Graduate School of Veterinary, Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mizuguchi","sequence":"additional","affiliation":[{"name":"Department of Developmental Medical Sciences, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Hirotsu","sequence":"additional","affiliation":[{"name":"Hirotsu Clinic, Kawasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Kurashiki Central Hospital, Kurashiki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kadota","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Oita University Faculty of Medicine, Yufu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingoro","family":"Shimada","sequence":"additional","affiliation":[{"name":"St. Marianna University School of Medicine, Kawasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the S-021812 Clinical Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0002679"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2005.10.002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1162-1167.2001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70199-9"},{"key":"e_1_3_2_6_2","unstructured":"Centers for Disease Control and Prevention. 2009. Drug susceptibility of swine-origin influenza A (H1N1) viruses April 2009. MMWR Morb. Mortal. Wkly. Rep. 58:433\u2013435. http:\/\/www.cdc.gov\/mmwr\/PDF\/wk\/mm5816.pdf."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3403-3408.2001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/598513"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/591851"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-002-0140-3"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.03.003"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000154322.38267.ce"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.21.3234"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00474-10"},{"key":"e_1_3_2_15_2","volume-title":"Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother","author":"Kohno S.","year":"2009","unstructured":"KohnoS. . 2009. Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a phase III, randomized, double-blind trial, abstr. V-537a. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.2.212"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X80297"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.1999.0602"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0531-5131(01)00359-4"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/135965350701200401","article-title":"Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus","volume":"12","author":"Medeiros R.","year":"2007","unstructured":"MedeirosR. . 2007. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir. Ther. 12:571\u2013576.","journal-title":"Antivir. Ther"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/651605"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4515-4520.2005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10190-3"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/314904"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)83026-X"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.suppl_2.23"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200020050-00005"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.182.9.1209"},{"key":"e_1_3_2_29_2","first-page":"1","article-title":"Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"58","author":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention","year":"2009","unstructured":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. 2009. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recommend Rep. 58:1\u20138.","journal-title":"MMWR Recommend Rep"},{"key":"e_1_3_2_30_2","unstructured":"National Institute of Allergy and Infectious Diseases. December 2004. Division of Aids table for grading the severity of adult and pediatric adverse events 1:1\u201320. http:\/\/www.hptn.org\/web%20documents\/HPTN046\/SSP\/Appendices\/AppendixE-ToxicityTables_DAIDS_AE_GradingTable_FinalDec2004.pdf."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(79)90362-2"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003410"},{"key":"e_1_3_2_33_2","unstructured":"World Health Organization. May 2010 posting date. Pandemic (H1N1) 2009 update 102. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/csr\/don\/2010_05_28\/en\/index.html."},{"key":"e_1_3_2_34_2","unstructured":"World Health Organization. February 2010. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/csr\/resources\/publications\/swineflu\/h1n1_guidelines_pharmaceutical_mngt.pdf."},{"key":"e_1_3_2_35_2","unstructured":"World Health Organization. April 2011 posting date. Cumulative number of confirmed human cases of avian influenza A\/(H5N1) reported to WHO. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/csr\/disease\/avian_influenza\/country\/cases_table_2011_04_26\/en\/index.html."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01718-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01718-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T01:26:07Z","timestamp":1686014767000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01718-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1128\/AAC.01718-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.01718-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"2010-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-03-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-05-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}